- NewsCategory：
- All Company news Industry news
common83One result
-
1031
Gotham Therapeutics Establishes Advanced Onco¥σεΩlogy Profiling Cascade with ProQinase to Prog∑∞ress its Portfolio of EpitranΩ¶♦scriptomic Drug Candidate™§Ω✔s
Gotham Therapeutics Establi™φαshes Advanced Oncology Profiling Casc ↓§¶ade with ProQinase to Progress←←↓× its Portfolio of Epitranscriptomic Drug Candid¶™≥atesWEDNESDAY, OCTOBER 30, 2019Gotham ¶€Therapeutics, a biotechnology company de♣>÷veloping a novel drug class targeting RNA♦©$↓-modifying proteins,&σ and ProQinase, an e ₽≤ arly stage drug-discovery compa$↕ ny, recently acquired by Malvern/↓β★λPA-based Reaction Biology Corp., today a✘₩nnounced that they have established an±¥☆≈ array of advanced biochemic×λal and cellular assays to charac™↓₽terize epitranscriptomic-directed compounds.“Es©δtablishing tailored target engagement, cell biology, phenotypic, and ₩Ω$in-vivo assays to evaluate compounds origi±βnating from our three most a♥¶$dvanced epitranscriptomic programs in parallel is a crucial next step to devel₹≤op our broad pipeline ✔>towards the clinic,” said Dr. Gerhard↓ ₽ Müller, Chief Scientifi∏™c Officer of Gotham Therapeutics. “By pursuing™< the full range of the reade₽£✘♠r-writer-eraser continuum, we are ₩×¥™able to focus on targets with the most compe★σlling links to disease and ad♥÷≤vance those programs in tandem.”“Combining >©our high proficiency in providing customized γεsolutions as early stage drug-di™₹scovery services, including tailor-made b®α←iochemical and cell-based assays, with Gotham’s ≤ expertise in epitranscriptomi∏✔cs, we were able to estabσ♦•Ωlish in a very short time a set of c®¥€λustomized enzymatic an>↑<d cellular assays for com×∞±βpounds addressing three different mRNA<α-modifying targets,” said Dr. Sebastian Dempe, C←δhief Executive Officer of ProQinase. “We look f♣✘♥orward to supporting Gotham as the company advan♣σces its programs into lead optimization and to cε₹πontinued work with the Gotham team assisting ≠∑the company to advance it™§s broad pipeline in a time-ef> ↕§fective manner.”In addit×≈∏ion to establishing a tailor-mad§≈e profiling cascade f∏ β→or compounds from its three most adva♠ nced programs, Gotham has also made≥≠ progress in strengthening its drug discov↓λ£ery engine and developing its candidat♠βe base. Gotham previously completed the ge™ ≤Ωne-to-lead phase for its ≤α↔₽drug discovery project targeting the METTL3/ME✔₩≥TTL14 complex and established a robust dis©♦•♥covery process as a platform for futur↕"e projects. The company has also generated a li☆≤£brary of high-quality cφ±←₩ompounds tailor-made fεor accelerated hit generation and hit-to-lead exp✔"✘ansion against large parts of the epitranscri₩φ✘÷ptomic target space. This library includes a ∑φ≥©collection of over 2,000 analogues covering ¥∏ over 80 distinct chemotypes t★γhat will be used to further accel™↓÷€erate Gotham’s drug discovery efforts as ≈γit expands its pipelin ¶ ©e.The original link:https://www.pharma ∏focusasia.com/news/go ₽tham-therapeutics-establishes-advan₩∑δced-oncology-profiling-cascade-with-proqinase-to-€∏progress-its-portfolio-of-epitranscriptom♦≥ic-drug-candidates2019 Asia-pacific pharma IP Lea¥π&der Summit: http://en©®≈.zenseegroup.com/p/510934/will be hel>↓≠d in Beijing on Novemberσ₽"σ 14-15, and will attract more than 500 indus ¶€πtry experts from domes↑₹₩✘tic and foreign pharmaceutical companies, ✔ biotechnology companies, gov πernments, associations, law firm★α¶αs, intellectual property agent÷Ω✔s and other companies to attend.Official regα•→™istration and consultation channels:Con ≥÷tact：AnnPhone: 021-6565≤$0305Email：Marketing@zenseegroup→÷≤.comhttp://en.zenseegroup.₽♦com/p/510934 -
1030
Gilead and Glympse Bio Announce Strate±¥λgic Collaboration for Use of Biomar♠<'ker Technology in NASH Clin↑←ical Development
Gilead and Glympse Bio Anno¥πunce Strategic Collaboration for Us₩♠<e of Biomarker Technology in NASH Clinical De£→↕velopmentTUESDAY, OCTOBER 29γ→, 2019Gilead Sciences Inc. and Glympse λ®Bio, Inc., today announced that the companies h←←∑ave entered into a strategic ≈φ☆collaboration in nonalcohol↑'♦ic steatohepatitis (NASH) clin≤₽ical development. Glympse Bio’s pro§♣prietary synthetic biomarkers – bioengine≤≈♦≥ered to identify stage an ↔d progression of disease '®→↔as well as early detection of ×£αtreatment response –↔→ will be used to determine clinical trial parα₽ticipants’ stage of disease↓$∞ at initial screening and to dete♦Ω₹'rmine responses to study treatment in Gilead♣✔’s NASH clinical progr©★am.“We are excited about the opportunity t✘αo partner with Glympse Bio to help inα$Ωform our NASH development program,” said Mani ↕★÷λSubramanian, MD, PhD Senior Viceδ∞• President, Liver Diseases, Gilead Sciences.↔" “By utilizing this innovative technology, we ←λ∞♥hope to better characterize this complex d♣£isease and improve our understanding of hoεΩw our compounds impact ®§α¶disease progression.”Glympse B≥™io’s proprietary technology, Glympse Inside™≥γ★, combines synthetic biomarkers with machine↓ learning approaches to identify the staβ'¥γge and monitor progression of important, comple≈≥"x diseases such as c♦αancer, fibrosis, infl ≥£§ammation, and infections, in real t"↓γime.“We are very excited about pa↑"rtnering with Gilead, a leader in©δ drug development, to ₩★help drive earlier and more favorable outcε←Ωomes for patients,” said Caroline J Loew, ™←∞President and CEO, Glympse Bio. “Gilead’s com"∏↔mitment to developing in®↔novative medicines in areas of hα☆igh unmet medical need aligns wit☆☆h our mission of transforming dis→↑♠÷ease detection and measu≥↓★ring treatment response, all with the§✘₹ goal of helping improve the lives of patients.”✔÷π←information source:pharma focus AsiaThe oriγ≠¶®ginal link:https:http₩↔∞ s:https://www.pharmafocu >®sasia.com/news/gilead-aα→≠nd-glympse-bio-announce-s✘≠trategic-collaboration-for-use-♥÷of-biomarker-technology-in™φ♣-nash-clinical-development2019 Asia-pa÷$>≤cific pharma IP Leader Summit:http://en.zense <egroup.com/p/510934/ wil ¶✘✔l be held in Beijing on&nb©♦×λsp;November 14-15, and will attract mor↕αγe than 500 industry experts from domestic±®'$ and foreign pharmaceutical companies, bi§↓λotechnology companies, governmentsε , associations, law firms, intellectual property∑≠ agents and other compan'∏ies to attend.Official registrati<Ω≈on and consultation channels:Contact：AnnPhone✔↑: 021-65650305Email：Marketing@§$π☆zenseegroup.comhttp://en.ze∞∑δ nseegroup.com/p/510934 -
1029
HistoIndex Announces Globaφ←l Partnerships To Ex∞∑pand AI-Based Digital Pathology Platfo♥←"rm
HistoIndex Announces Globa★맶l Partnerships To Expand AI-Bas☆§™ed Digital Pathology Platform←←€£MONDAY, OCTOBER 28, 2019HistoIndex®↑ announces the expansion of ↑φ×λits AI-based digital patho♠φ€logy platform towards larg¥σe-scale NASH preclinical programs for pharmacσ≤eutical and biotech companies to achiα÷eve quantifiable and reproducible data on♠♣ therapeutic responses in NASH animal models, and≤♣σ to aid CROs as well as research agencies in va♠α₹lidating new models mimic♦$king the NASH disease.Published preclinical ∏studies have demonstrated the use of HistoI♠↔πndex's fully quantifiable Second Harm♦onic Generation (SHG) te"φchnology as a highly accura♠¥te stain-free method that can monitor the ef₽₽ficacy of various the≠®✘rapeutic agents, by quantifyin₩↔g more than 450 NASH-associated parame↔•π"ters in fibrosis, inflammation, ballooning a£ε☆÷nd steatosis. The infor↑≥★✘mation of these NASH-&Ω•Ωassociated parameters gathered from the e×∑★ ntire liver tissue, provides compreh✘≈≤ensive insights on the me₽✘chanism of action of the therapeutic✘↑ agent. As a drug discovery ×↔÷tool, HistoIndex's SHG-enabled← × digital pathology platform will allow →σ÷✔pharmaceutical and biotech companies π™to select promising lead c∏←andidates for further optimiz£σ÷ation and make informed ★♥≥decisions in the management of≠λ their NASH drug develλ♣×opment pipeline.In addition to onδ↓¥→going NASH clinical trials, HistoIndex is currently involved in multiple precl&Ωinical studies, most of which a♦→re conducted by major ph>δarmaceutical and biotech companies, medical÷€ universities, CROs and researc¶€h agencies. Notably, HistoIndex has recentlε∞y entered into a collaboration with the A ★*STAR's Genome Institute of Singapore (GIS) t↑ o validate their in viv™↑o and in vitro NASH models based∞•σ¥ on Asian-centric clinical data.♥∑ Says Professor Patrick Tan, Executive Directo¶≠r of the Genome Institut±§e of Singapore (GIS), "At GIS, we ©σ₹♣conduct our preclinical studies ♠on fatty liver involvin♥£ g data from animal models based on patient¶α¶-derived transcriptomic data. Thiγ↔∑s has a high translation★γal potential as it helps us to →λ♣↑pinpoint new therapeutic ta←→∏rgets and their validation. Therefore, usi®÷♥ng a fully quantitative, reliab≤©₽le and objective pathoα>logical evaluation such πas HistoIndex's AI-based digital paΩ♥≈thology platform is essential to the succesβ♣s of our efforts in therap∞™₩Ωeutic target discovery."Histoα•Index is also a partner with globallyσ€-renowned CRO, WuXi Apptec, in advancing their NA≤SH preclinical programs with advanced ™¥R&D and smart imaging analy®≈sis capabilities. Published study ∏λ™data will be available fo₽•r discussions during networking opportunities β✘α"throughout AASLD's The Liver Meeting® i↕§n November 2019. "We are very •δ™excited to extend our AI-based SHG platform t׶o preclinical studies to help δ>companies with drug discovery programs sel∏♦ect promising lead candidates for further opt§♦∑§imization and subsequent clinical devel✘ ±opment," says Dr Poon Thong ←∏♥αYuen, Chief Executive Officer of Hi€φstoIndex. "Our SHG image analysis platfo©Ωrm has already been used to β©↔™analyze the efficacy of a series ↓€♦of promising drug ca₽>→ndidates for NASH within vari↑↔ous animal models commonlγ∑εy-used by the industry, and we♣ believe these preclinic₩>al partnerships will he☆lp drive the adoption of our ©♣platform significantly."information so∏urce:pharma focus AsiaThe original link:https:ht© tps://www.pharmafocusasia.com/news/histoi±↓±ndex-announces-global-partnerships-to-ex®¶$€pand-ai-based-digital-pathology-platform2019 A ≠¶sia-pacific pharma IP Leader Summit: ×™δ↕http://en.zenseegroup.com/p/510934/will be held i≥αn Beijing on&nb÷♥sp;November 14-15, and will attract more tha¶αn 500 industry experts from domesticγδ← and foreign pharmaceutical compa•ε&nies, biotechnology companies, governments, as×∞sociations, law firms, intellectual pr&&operty agents and other companies to att≈<≤₽end.Official registrati$∑↓•on and consultation channels:Contacβπt：AnnPhone: 021-65650305Email：Marketing@±σ¥♦zenseegroup.comhttp://en.zenseegroup.com☆♥™/p/510934 -
1028
AVROBIO Receives Orphan-Drug Designation♣π≤ from the U.S. FDA for AV≤™R‑RD‑02 for the Treatment of ✔™ΩGaucher Disease
AVROBIO Receives Orphan-Drug Designatλ≤↓ion from the U.S. FDA for AVR‑RD‑02 for the T↔•↓↕reatment of Gaucher DiseaseF®≥σRIDAY, OCTOBER 25, 2019AVROBIO, In✘ c., today announced that the U.S. Food a≥∏•nd Drug Administration (FDA) has granted ÷orphan-drug designation for the Company’s inv>€÷€estigational gene therapy, AVR-RD-02, for t♣★↕he treatment of Gaucher disease. AVR-RD-02 φ★consists of the patient’s ow∏&πn hematopoietic stem cells, gene♥ £tically modified to express glucocerebrosida♦'se (GCase), the enzyme that is deficient∞♥ in Gaucher disease. The ×✘ε'Company is actively recruiting in Canada for its ✔≥Phase 1/2 clinical trial of AVR-RD-02, which seek±≥δs to evaluate the safety and efficacy ε™of the therapy in patie' ✔nts with Type 1 Gaucher disease.“Under the e↑™π≥xisting standard of care, pa™π♥&tients with Gaucher disease are b↓≤>ound to a lifelong infusion schedule of enz®♥←yme replacement therapies, and still experience×¥ painful and progressive symptoms such as ♠±∏®debilitating musculoskeletal pain and 'λ×fatigue,” said Birgitte Volck, MD, PhD, Presi¥ dent of Research and Dev↑∞γelopment at AVROBIO. “Orp™←'→han-drug designation recognizes the ✘ unmet need of populat↕×εions with rare diseases like Ga↕ ✔₩ucher where AVROBIO strives to transform liveΩ"s by addressing the under•✔φlying cause of the diseβαase with a single dose ofε€£♥ gene therapy.”Orphan-drug designatiαΩγon is granted by the Fε∏DA to drugs and biologics which are intended π₽for the safe and effective treatment, di$←agnosis or prevention of rare diseas"₹ >es or conditions that a→♥☆ffect fewer than 200,000 people in the€$ United States. Orphan-drug designation provide×®s certain incentives, which may include tax crediλ∏ts towards the cost ✘>of clinical trials and prescri ≈λ≈ption drug user fee waivers.information so ↔urce:pharma focus AsiaThe original link:ht÷•≈↓tps:https://www.pharmafocus≠¶₹₽asia.com/news/avrobio-re¶∑ceives-orphan-drug-designation-from-the-us-fdλ a-for-avrrd02-for-the-treatment-o✔∏→±f-gaucher-disease2019 Asia-pacific pharmεφa IP Leader Summit: http://en.↔≈zenseegroup.com/p/510934/will be held in&≈Ωnbsp;Beijing on&nδ★σγbsp;November 14-15, and will attract mo↕'¥ re than 500 industry experts from domes₩& tic and foreign pharmaceutical companies, biotec✘∑hnology companies, go¶☆↓πvernments, associations, la↔×<'w firms, intellectual property agents and other cΩ≠≥♦ompanies to attend.Offic↔γ→δial registration and consultation chγγannels:Contact：AnnPhone: 021-65650305Emaε&il：Marketing@zenseegroup.comhttp://en. ♥zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation-Targe &→ted Pipeline Through Acquisit↕↑ion of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies♠♥♣✘, Inc., a biopharmaceutical c₩₹≠ompany developing ther'₩↕apeutics to extend b↕ε✘rain health, today announced the acquisition oσ ∞f Smith Therapeutics, a private bi&±₹≈opharmaceutical company¶← with a shared goal of targeting neuroinflam↔₹mation to treat neurodegenerative disease. Smit →↕h Therapeutics’ Founder and Chief Executive O™→☆$fficer Philip Ashton-Rickardt, Ph.D., hasΩ↓↑™ joined the senior lead₽₽∏€ership team at AZTherapies as Senior Vice Preside♥♥€☆nt of Immunology. Financial terms of the acq♥λ$✔uisition were not disclosed♠™¥↕.Smith Therapeutics’ proprieta'™ry research platform focuses on the use ∞≤of modified T cells to restore a ♥$healthy balance of inflammato→αry and regulatory cells in the brain. To date, π" Smith has successfully engin↔♦₩♣eered immunosuppressive T₩β"≠ regulatory (Treg) cells wi÷γεth Chimeric Antigen Receptors (¶↕≥CARs) targeting brain glial ce♠×$lls. Previous research has demon§¶$strated the ability εφ ¶of Tregs to dampen microglial activitβ✔y and reduce neuroinflammation in mσ"₩$odels of neurodegeneration,επ suggesting their potential utilit↑£€±y in the treatment of diseases inc✔∑♠luding Progressive Supranuclear Palsy• >≤ (PSP), Alzheimer’s disease, Parkinson’←σ's disease, Huntington’s disease, &±γ✔Amyotrophic Lateral S•$£¥clerosis (ALS), and others.“This acquisition ¶₩represents a meaningful step forwar↕'₹§d for us as we continue to strengthen our leader♦↓σ¥ship position in the development of therapie↔¶♦s targeting neuroinflammation tσ£★o stop or slow the progression of neurod×✘₹egenerative diseases,” said David R. E∑€lmaleh, Ph.D., Founder,®™↔☆ CEO, and Chairman of AZTherapies. “We are✔"± excited to be workingα with Philip as we add this cutting-e £×dge technology to our portfolio of inno>←vative programs. An est→≈eemed immunologist and inventor of the techβ±nology, Philip brings unparal×↕÷&leled expertise to the compα§any and we look forward to advancing this CAR-Tr÷→eg program further into IND-enablin↕π♣<g studies and into clinic÷∑'≥al development as rapidly as possibl™•≥∞e.”Dr. Ashton-Rickardt commentγ₹ed on the acquisition and h®↓♣is appointment: “Our sha≤₹γ§red rationale of targeting neuroin✘σ♥flammation as the root cause o × ✘f neurodegenerative disease makes this×₽©≥ acquisition a great strategic fit for♣÷✘ us. With AZTherapies’ e•α$xpertise in drug deve§♠lopment and clinical tria₩"l execution, we believe tha∑•↑t together, we are well positioned to advan§£ce our CAR-Treg technology and fundamentally c ≥hange neurodegenerati✘♥ve disease progression.”Prior to launching ←₽₽↑Smith Therapeutics in 2017, ↑¶Dr. Ashton-Rickardt was Chairα in Immunology at Imperial College L¶Ω¶ondon, Visiting Profe€↕ssor, Brigham and Women’s Hospital, H®arvard Medical School, and Associate≥< Professor in the Department of Pathology at th ∑e University of Chicago. His work has beeφσβn recognized by his peers th♦←rough the award of tenure from The University of ↔→→λChicago and by his fellow citiz>φens as a recipient of the Early Career Awa♦<₽rd for Scientists and Engineeγ☆®rs from President Bill C ≠βlinton. He has published more than 65 peer-r$>±εeviewed papers in more©∏ than 30 academic journa↓☆€ls (including Cell, Scie✘ ÷®nce, Immunity, and Nature Immunology), ha±≤₹s served as an editor for several ac✘÷ademic journals, and has been a member ★λ of grant review boards globally. Dr. Ashton™→-Rickardt received a B™✘±.Sc. in Biochemistry from thασ∏♣e University of London, King&<←’s College with honors,✔≥" a Ph.D. in Molecular Biol±↑♣≈ogy from the University of ™≤©γEdinburgh, and completed posπ♦t-doctoral work at the University of Edinbur¶↑↕γgh and the Massachusetts Institute of •™→•Technology in Molecular Biolo•←∞gy and Molecular Immunology, respectively.info↕÷λrmation source:pharma focus AsiaT↕'Ω∞he original link:https:htt →∑ps://www.pharmafocusasia.com/news/azthera₹×≈pies-strengthens-neuroinflammatio✔'××n-targeted-pipeline-throug™β>h-acquisition-of-smith-therap≈₹&eutics2019 Asia-pacific pharma IP Leader S≥'ummit: http://en.zenseegroup.com/p/5109δ♣↕₽34/will be held in Beijing &nbsα•₽p;on November 14-15, and willσ↑ attract more than 500 industry experts from do≈ Ωmestic and foreign pharmaceutical companies, bio≈←•technology companies, governm"¥✘↓ents, associations, law firms, i₽π☆™ntellectual property ag>≈×±ents and other companies to attend.O≥®δ✔fficial registration and consultat σ↕ion channels:Contact：An₽§nPhone: 021-65650305Email：Marketing@zenseegα↔™roup.comhttp://en.zenseegroup.com/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016